Freenome, a biotech company specializing in AI-driven blood tests for early cancer detection, is rated Buy due to its FDA-approved SimpleScreen CRC test and a strong $410 million cash reserve. The company has licensed SimpleScreen CRC to Abbott, which could generate up to $700 million in milestone payments and 10% royalties. The next major catalyst is the PROACT LUNG study, which aims to validate their multiomics platform for lung cancer detection. Trading near its fair value of $18.02 per share at $17.00, Freenome has significant upside potential if lung cancer data proves positive and commercial execution succeeds.
Freenome's recent developments provide context for the health sector's performance on Pluang. As of Sep 22, 2026 23:13 WIB, 76 of 101 priced health-sector US stocks rose while 25 fell. Notable movers include HRTX at USD 0.29 with a 7.00% increase and a typical hold time of 34 days, NUWE at USD 0.83 down 5.52%, and DGX at USD 231.84 down 5.32%.
Royal Caribbean is close to securing a $3 billion deal to acquire a 50% equity stake in Sandals, valuing the Caribbean resort chain at $6 billion. This move aims to expand Royal Caribbean's presence in land-based vacations, complementing its cruise b...
Apple is developing a new screen-less fitness tracker, described as a thin fabric band with sensors, to compete with Whoop. The product is still in the exploratory phase, with prototypes made, and is not expected to launch before 2028. This new devic...
Meta Platforms reported a 28% year-over-year revenue increase to $60.8 billion in Q2, surpassing expectations. The market's focus on Meta's slightly increased capital expenditures, mainly due to external component costs, overshadowed the company's em...
White-hat researchers have secured 52.37 Bitcoin worth over $4.5 million from the Coldcard hardware wallet exploit, which involved a firmware bug causing weak seed generation. The recovered funds, about 2.8% of the total stolen, are now held by Crypt...
Berkshire Hathaway has acquired nearly a 10% stake in Miami-based homebuilder Lennar, purchasing about 2.7 million Class A shares worth $1.8 billion. This move comes as Lennar reported weak third-quarter earnings and forecasted lower-than-expected gu...
